Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination
© 2024. The Author(s)..
Although young children generally experience mild symptoms following infection with SARS-CoV-2, severe acute and long-term complications can occur. SARS-CoV-2 mRNA vaccines elicit robust immunoglobulin profiles in children ages 5 years and older, and in adults, corresponding with substantial protection against hospitalizations and severe disease. Whether similar immune responses and humoral protection can be observed in vaccinated infants and young children, who have a developing and vulnerable immune system, remains poorly understood. To study the impact of mRNA vaccination on the humoral immunity of infant, we use a system serology approach to comprehensively profile antibody responses in a cohort of children ages 6 months to 5 years who were vaccinated with the mRNA-1273 COVID-19 vaccine (25 μg). Responses are compared with vaccinated adults (100 μg), in addition to naturally infected toddlers and young children. Despite their lower vaccine dose, vaccinated toddlers elicit a functional antibody response as strong as adults, with higher antibody-dependent phagocytosis compared to adults, without report of side effects. Moreover, mRNA vaccination is associated with a higher IgG3-dependent humoral profile against SARS-CoV-2 compared to natural infection, supporting that mRNA vaccination is effective at eliciting a robust antibody response in toddlers and young children.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature communications - 15(2024), 1 vom: 30. Jan., Seite 905 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nziza, Nadège [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV Vaccine mRNA-1273 |
|---|
| Anmerkungen: |
Date Completed 01.02.2024 Date Revised 01.03.2024 published: Electronic UpdateOf: Res Sq. 2023 Apr 06;:. - PMID 37066325 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-024-45181-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36781403X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36781403X | ||
| 003 | DE-627 | ||
| 005 | 20240301232426.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240131s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-024-45181-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM36781403X | ||
| 035 | |a (NLM)38291080 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nziza, Nadège |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2024 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateOf: Res Sq. 2023 Apr 06;:. - PMID 37066325 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Although young children generally experience mild symptoms following infection with SARS-CoV-2, severe acute and long-term complications can occur. SARS-CoV-2 mRNA vaccines elicit robust immunoglobulin profiles in children ages 5 years and older, and in adults, corresponding with substantial protection against hospitalizations and severe disease. Whether similar immune responses and humoral protection can be observed in vaccinated infants and young children, who have a developing and vulnerable immune system, remains poorly understood. To study the impact of mRNA vaccination on the humoral immunity of infant, we use a system serology approach to comprehensively profile antibody responses in a cohort of children ages 6 months to 5 years who were vaccinated with the mRNA-1273 COVID-19 vaccine (25 μg). Responses are compared with vaccinated adults (100 μg), in addition to naturally infected toddlers and young children. Despite their lower vaccine dose, vaccinated toddlers elicit a functional antibody response as strong as adults, with higher antibody-dependent phagocytosis compared to adults, without report of side effects. Moreover, mRNA vaccination is associated with a higher IgG3-dependent humoral profile against SARS-CoV-2 compared to natural infection, supporting that mRNA vaccination is effective at eliciting a robust antibody response in toddlers and young children | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Deng, Yixiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wood, Lianna |e verfasserin |4 aut | |
| 700 | 1 | |a Dhanoa, Navneet |e verfasserin |4 aut | |
| 700 | 1 | |a Dulit-Greenberg, Naomi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Tina |e verfasserin |4 aut | |
| 700 | 1 | |a Kane, Abigail S |e verfasserin |4 aut | |
| 700 | 1 | |a Swank, Zoe |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Jameson P |e verfasserin |4 aut | |
| 700 | 1 | |a Demokritou, Melina |e verfasserin |4 aut | |
| 700 | 1 | |a Chitnis, Anagha P |e verfasserin |4 aut | |
| 700 | 1 | |a Fasano, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Edlow, Andrea G |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Nitya |e verfasserin |4 aut | |
| 700 | 1 | |a Horwitz, Bruce H |e verfasserin |4 aut | |
| 700 | 1 | |a McNamara, Ryan P |e verfasserin |4 aut | |
| 700 | 1 | |a Walt, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Lauffenburger, Douglas A |e verfasserin |4 aut | |
| 700 | 1 | |a Julg, Boris |e verfasserin |4 aut | |
| 700 | 1 | |a Shreffler, Wayne G |e verfasserin |4 aut | |
| 700 | 1 | |a Alter, Galit |e verfasserin |4 aut | |
| 700 | 1 | |a Yonker, Lael M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 30. Jan., Seite 905 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:30 |g month:01 |g pages:905 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-45181-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 30 |c 01 |h 905 | ||